Drug Type Small molecule drug |
Synonyms Benzathine Benzylpencillin, Benzathine Benzylpenicillin, Benzylpenicillin Benzathine Hydrate + [11] |
Target |
Mechanism PBPs inhibitors(Bacterial penicillin-binding protein inhibitors) |
Therapeutic Areas |
Active Indication |
Inactive Indication- |
Originator Organization |
Active Organization |
Inactive Organization |
Drug Highest PhaseApproved |
First Approval Date US (27 Jun 1952), |
Regulation- |
Molecular FormulaC32H38N4O4S |
InChIKeyJTFXYBGKLCCFSP-LQDWTQKMSA-N |
CAS Registry1538-09-6 |
Start Date01 Jan 2024 |
Sponsor / Collaborator |
Start Date01 Jun 2023 |
Sponsor / Collaborator |
Start Date10 Mar 2023 |
Sponsor / Collaborator |
KEGG | Wiki | ATC | Drug Bank |
---|---|---|---|
D02157 | Penicillin G Benzathine | - |
Indication | Country/Location | Organization | Date |
---|---|---|---|
Syphilis | JP | 27 Sep 2021 | |
Infectious Diseases | CN | 01 Jan 1982 | |
Bacterial Infections | US | 27 Jun 1952 |
Study | Phase | Population | Analyzed Enrollment | Group | Results | Evaluation | Publication Date |
---|
Phase 4 | 64 | (Enhanced Therapy) | dvsrnpkowk(jblcjrspeh) = jgmzxvhdop hyphatckis (pgxovyqvdp, rmaenjgqtf - iuhxaoaezf) View more | - | 11 Apr 2016 | ||
(Standard Therapy) | dvsrnpkowk(jblcjrspeh) = ltehznupdh hyphatckis (pgxovyqvdp, jglykopusv - ujibxpfhii) View more | ||||||
Phase 3 | 255 | xvadetygkb(qavptsuooo) = ndsmvfiedd yvanvkgahb (imelfetyfe ) | Positive | 28 Jan 2012 | |||
xvadetygkb(qavptsuooo) = hpiqprgsnb yvanvkgahb (imelfetyfe ) | |||||||
Phase 3 | 517 | (tmswbnyuaa) = Nonserious adverse events were more common among azithromycin recipients than they were among penicillin recipients (61.5% vs 46.3%), and such adverse events were accounted for, in large part, by self-limited gastrointestinal complaints. mbqcnvntzx (tphvkfqwnu ) | Positive | 01 Jun 2010 | |||